Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.63 |
| ▸ | DDB1 | Q16531 | 17/20 | 0.63 |
| ▸ | GSPT1 | P15170 | 2/20 | 0.51 |
| ▸ | PDE6D | O43924 | 1/20 | 0.49 |
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL29493526 | 1.00 | CRBN (0.63) | CRBNDDB1GSPT1PDE6DSTAT3 | |
| Trifluoroacetic Acid SCHEMBL19747583 | 1.00 | CRBN (0.63) | CRBNDDB1GSPT1PDE6DSTAT3 | |
| Trifluoroacetic Acid SCHEMBL19747894 | 1.00 | CRBN (0.63) | CRBNDDB1GSPT1PDE6DSTAT3 | |
| Trifluoroacetic Acid SCHEMBL23705500 | 0.93 | CRBN (0.65) | CRBNDDB1GSPT1STAT3 | |
| SCHEMBL29400195 | 0.93 | CRBN (0.66) | CRBNDDB1GSPT1 | |
| SCHEMBL22636514 | 0.93 | CRBN (0.66) | CRBNDDB1GSPT1 | |
| SCHEMBL29098509 | 0.93 | CRBN (0.66) | CRBNDDB1GSPT1 | |
| SCHEMBL20919944 | 0.93 | CRBN (0.66) | CRBNDDB1GSPT1 | |
| SCHEMBL19747744 | 0.93 | CRBN (0.66) | CRBNDDB1GSPT1 | |
| SCHEMBL29403213 | 0.93 | CRBN (0.66) | CRBNDDB1GSPT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115666575-B | Compounds and uses thereof | 福宏治疗公司 | 2024-12-10 | — | — | CN | disclosed |
| US-20240263184-A1 | METHODS OF ALTERING GENE EXPRESSION BY PERTURBING TRANSCRIPTION FACTOR MULTIMERS THAT STRUCTURE REGULATORY LOOPS | PIONEERING MEDICINES 08- B, INC. | 2024-08-08 | — | — | US | disclosed |
| US-11873496-B2 | Methods of altering gene expression by perturbing transcription factor multimers that structure regulatory loops | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2024-01-16 | — | — | US | disclosed |
| CN-116867785-A | Compounds and uses thereof | 福宏治疗公司 | 2023-10-10 | — | — | CN | disclosed |
| EP-4249501-A2 | METHODS OF ALTERING GENE EXPRESSION BY PERTURBING TRANSCRIPTION FACTOR MULTIMERS THAT STRUCTURE REGULATORY LOOPS | Whitehead Institute for Biomedical Research (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-3565891-B1 | METHODS OF ALTERING GENE EXPRESSION BY PERTURBING TRANSCRIPTION FACTOR MULTIMERS THAT STRUCTURE REGULATORY LOOPS | WHITEHEAD INST BIOMEDICAL RES (US) | 2023-04-12 | — | — | EP | disclosed |
| US-11505560-B2 | Heterobifunctional compounds with improved specificity | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| WO-2022109396-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-11285218-B2 | Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240263184-A1 | METHODS OF ALTERING GENE EXPRESSION BY PERTURBING TRANSCRIPTION FACTOR MULTIMERS THAT STRUCTURE REGULATORY LOOPS | CTCF, JUN, ELF3 | CRBN 805/4885DDB1 180/4885GSPT1 954/4885 |
| US-11873496-B2 | Methods of altering gene expression by perturbing transcription factor multimers that structure regulatory loops | CTCF, JUN, ELF3 | CRBN 805/4885DDB1 180/4885GSPT1 954/4885 |
| US-11505560-B2 | Heterobifunctional compounds with improved specificity | MDM2, STUB1, UBE3C | CRBN 113/4885DDB1 249/4885GSPT1 2550/4885 |
| US-11285218-B2 | Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use | BRD9, BRWD1, BRD1 | CRBN 186/4885DDB1 442/4885GSPT1 1844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.